FDA Approves Previously Rejected Muscular Dystrophy Treatment

The drug Vyondys 53 has met a surrogate endpoint of protein production, but there ’s no clear proof it has a clinical benefit.
Source: The Scientist - Category: Science Tags: News & Opinion Source Type: news